- Home
- SLN vs PKE Comparison
SLN vs PKE Comparison
Compare SLN & PKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- PKE
- Stock Information
- Founded
- SLN 1994
- PKE 1954
- Country
- SLN United Kingdom
- PKE United States
- Employees
- SLN N/A
- PKE N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- PKE Military/Government/Technical
- Sector
- SLN Health Care
- PKE Industrials
- Exchange
- SLN Nasdaq
- PKE Nasdaq
- Market Cap
- SLN 281.0M
- PKE 260.2M
- IPO Year
- SLN N/A
- PKE N/A
- Fundamental
- Price
- SLN $5.92
- PKE $14.63
- Analyst Decision
- SLN Buy
- PKE
- Analyst Count
- SLN 5
- PKE 0
- Target Price
- SLN $32.60
- PKE N/A
- AVG Volume (30 Days)
- SLN 111.7K
- PKE 54.8K
- Earning Date
- SLN 08-14-2025
- PKE 07-15-2025
- Dividend Yield
- SLN N/A
- PKE 3.40%
- EPS Growth
- SLN N/A
- PKE N/A
- EPS
- SLN N/A
- PKE 0.29
- Revenue
- SLN $27,701,000.00
- PKE $62,026,000.00
- Revenue This Year
- SLN N/A
- PKE N/A
- Revenue Next Year
- SLN N/A
- PKE N/A
- P/E Ratio
- SLN N/A
- PKE $50.93
- Revenue Growth
- SLN N/A
- PKE 10.75
- 52 Week Low
- SLN $1.97
- PKE $11.96
- 52 Week High
- SLN $22.47
- PKE $15.57
- Technical
- Relative Strength Index (RSI)
- SLN 58.35
- PKE 67.95
- Support Level
- SLN $5.33
- PKE $13.53
- Resistance Level
- SLN $6.00
- PKE $14.92
- Average True Range (ATR)
- SLN 0.44
- PKE 0.34
- MACD
- SLN -0.03
- PKE 0.08
- Stochastic Oscillator
- SLN 64.07
- PKE 89.21
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About PKE Park Aerospace Corp.
Park Aerospace Corp designs develop and manufactures engineered, advanced composite materials and composite structures and assemblies and low-volume tooling for the aerospace markets and prototype tooling for such structures and assemblies. Geographically, the company derives a majority of revenue from North America and also has a presence in a company operates its business in Asia and Europe. It offers advanced composite Prepregs for Aircraft Structures and Interiors, Sigma Strut and Alpha Strut.